

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A method for ~~inhibiting the growth and/or spreading of~~
treating urokinase associated malignant tumors, metastases and/or lung foci a
malignant tumor selected from the group consisting of urokinase associated breast
cancer and lung foci resulting from metastases thereof, and urokinase associated
pancreatic cancer and liver foci resulting from metastases thereof, comprising
administering a composition comprising $N\alpha(2,4,6\text{-Triisopropylphenylsulfonyl})\text{-3-}$
amidino-(D,L)-phenylalanine 4-ethoxycarbonylpiperazide, the L enantiomer thereof
or a pharmaceutically suitable salt thereof and a pharmaceutically acceptable carrier
to a patient in need of such inhibition.
2. (Original) The method according to claim 1, wherein said tumor affects lymphatic
tissue.
3. (Original) The method according to claim 2, wherein said lymphatic tissue is
lymph nodes.
4. (Original) The method according to claim 3, wherein said lymph nodes are
selected from the group consisting of axillary lymph nodes and intraperitoneal lymph
nodes.

5. (Original) The method according to claim 1, further comprising administering a cytotoxic substance.
6. (Previously Presented) The method according to claim 5, wherein said cytotoxic substance is selected from the group consisting of cisplatin, carboplatin, doxorubicin, epirubicin, 5-fluorouracil and a taxane.
7. (Original) The method according to claim 6, wherein said taxane is paclitaxel.
8. (Canceled)
9. (Original) The method according to claim 1, wherein said composition is administered once daily to once weekly.
10. (Original) A pharmaceutical composition comprising $\text{Na}(2,4,6\text{-Triisopropylphenylsulfonyl})\text{-3-amidino-(D,L)-phenylalanine 4-ethoxycarbonylpiperazide}$, the L enantiomer thereof or a pharmaceutically suitable salt thereof, an additional, pharmacologically active substance, and a pharmaceutically acceptable carrier.

11. (Original) The pharmaceutical composition according to claim 10, wherein said additional, pharmacologically active substance is selected from the group consisting of radio labels or cytotoxic substances.

12. (Original) The pharmaceutical composition according to claim 11, wherein said additional, pharmacologically active substance is a cytotoxic substance.

13. (Previously Presented) The pharmaceutical composition according to claim 12, wherein said cytotoxic substance is selected from the group consisting of cisplatin, carboplatin, doxorubicin, epirubicin, 5-fluorouracil and a taxane.

14. (Original) The pharmaceutical composition according to claim 13, wherein said taxane is paclitaxel.

15. (Original) A kit comprising, in separate containers, a) N α (2,4,6-Triisopropylphenylsulfonyl)-3-amidino-(D,L)-phenylalanine 4-ethoxycarbonylpiperazide, the L enantiomer thereof or a pharmaceutically suitable salt thereof, and b) radio labels and/or cytotoxic substances.

16. (Currently amended) A method for the treatment of ~~urokinase-associated~~ malignant tumors selected from the group consisting of urokinase associated breast cancer and lung foci resulting from metastases thereof, and urokinase associated pancreatic cancer and liver foci resulting from metastases thereof comprising

- a) surgically removing a primary tumor from a patient, and
- b) administering a composition comprising $N\alpha(2,4,6\text{-Triisopropylphenylsulfonyl})\text{-3-amidino-(D,L)-phenylalanine 4-ethoxycarbonylpiperazide}$, the L enantiomer thereof or a pharmaceutically suitable salt thereof and a pharmaceutically acceptable carrier to said patient.

17. (Original) The method according to claim 16, further comprising administering cytotoxic agents and/or radiation therapy to said patient.

18. (Currently Amended) A method for ~~inhibiting the growth and/or spreading of~~
treating urokinase associated malignant tumors, metastases and/or lung foci
malignant tumors selected from the group consisting of urokinase associated breast
cancer and lung foci resulting from metastases thereof, and urokinase associated
pancreatic cancer and liver foci resulting from metastases thereof, comprising contacting a cell with a $N\alpha(2,4,6\text{-Triisopropylphenylsulfonyl})\text{-3-amidino-(D,L)-phenylalanine 4-ethoxycarbonylpiperazide}$, the L enantiomer thereof or a pharmaceutically suitable salt thereof, wherein said cell is in a patient in need of such ~~inhibition~~ treatment.

19. (Currently Amended) A method for ~~inhibiting the growth and/or spreading of~~
treating urokinase associated malignant tumors, metastases and/or lung foci
selected from the group consisting of urokinase associated breast cancer and lung

foci resulting from metastases thereof, and urokinase associated pancreatic cancer and liver foci resulting from metastases thereof in a patient in need of such ~~inhibition~~ treatment, comprising administering $\text{Na}(2,4,6\text{-Triisopropylphenylsulfonyl})\text{-3-amidino-}$ (D,L)-phenylalanine 4-ethoxycarbonylpiperazide, the L enantiomer thereof or a pharmaceutically suitable salt thereof, to a tumor cell in said patient.